Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Company Overview

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting.

Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.

Key Stats

• Today's Range: $6.00 to $6.26
• 50-Day Range: $5.56 to $7.46
• 52-Week Range: $4.00 to $7.65
• Volume: 1.19 million shs
• Average Volume: 1.63 million shs
• Market Capitalization: $343.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.33
• Consensus Rating: Hold

Abeona Therapeutics Stock Analysis - MarketRank™

Abeona Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 490th out of 918 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Abeona Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Abeona Therapeutics has a consensus price target of $19.33, representing about 221.7% upside from its current price of $6.01.

Amount of Analyst Coverage

Abeona Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.27) per share.

Price to Book Value per Share Ratio

Abeona Therapeutics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.86% of the float of Abeona Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Abeona Therapeutics has a short interest ratio ("days to cover") of 6.87.

Change versus previous month

Short interest in Abeona Therapeutics has recently increased by 4.63%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Abeona Therapeutics does not currently pay a dividend.

Dividend Growth

Abeona Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.35

News Sentiment

Abeona Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,674,433.00 in company stock.

Percentage Held by Insiders

7.10% of the stock of Abeona Therapeutics is held by insiders.

Percentage Held by Institutions

80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/26/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABEO
• Previous Symbol: OTCMKTS:ACCP
• CIK: 318306
• Web: www.abeonatherapeutics.com
• Phone: 214-665-9495
• Fax: 214-905-5101
• Employees: 90
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Abeona Therapeutics: $19.33
• High Price Target: $21.00
• Low Price Target: $17.00
• Potential Upside/Downside: +221.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $71.18 million
• Net Margins: N/A
• Pretax Margin: -306.81%
• Return on Equity: -41.69%
• Return on Assets: -30.36%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 6.63
• Quick Ratio: 6.40

Sales & Book Value

• Annual Sales: $5.82 million
• Price / Sales: 59.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.24 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 57,180,000
• Free Float: 53,124,000
• Market Cap: $343.65 million
• Optionable: Optionable
• Beta: 1.35